drugset
drugset / Trial / NCT05629806

Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes

NCT05629806 ↗

Phase 3 Unknown 50 enrolled Nanjing First Hospital, Nanjing Medical University
RandomizedCrossoverOpen-labelTreatment

Summary

Monotherapy with DPP-IV inhibitors, SGLT-2 inhibitors or insulin secretagogues frequently failed to maintain blood glucose in patients with type 2 diabtes. It was critical to determine which was more suitable of acarbose versus metformin plus pioglitazone.

Timeline

Start
2022-04-10
Primary completion
2023-05-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acarbose Unknown 50 mg —
Comparator Metformin Small molecule 500 mg Oral
Comparator Pioglitazone Small molecule 15 mg Oral

Indications

type 2 diabetes mellitus